ARIAD Pharmaceuticals

ARIAD Pharmaceuticals, Inc. was an American oncology company, now part of Takeda Oncology, which was founded in 1991 by Harvey J. Berger, M.D. and headquartered in Cambridge, Massachusetts. ARIAD engaged in the discovery, development, and commercialization of medicines for cancer patients.

ARIAD Pharmaceuticals, Inc.
Company typePublic
Traded as
Nasdaq: ARIA
IndustryPharmaceuticals, biotechnology
Founded1991
Defunct2017 (2017)
FateMerged with Takeda Pharmaceuticals
HeadquartersCambridge, MA, United States
Key people
Harvey Berger,
Founder, chairman, and CEO Emeritus
Alex Denner,
Chairman of the Board
Timothy P. Clackson,
President of Research and Development and Chief Scientific Officer
Ed Fitzgerald, (Former CFO)
Marty Duvall, (Former CCO)
ProductsPonatinib (FDA approved, trade name Iclusig)
Ridaforolimus (FDA approved)
Brigatinib (FDA approved)
Rimiducid (Under development)
AP32788 (Under development)
Revenue US$118.8 million (2015)
US$217.27 million (2015)
Net income
US$231.16 million (2015)
Total assets US$546.69 million (2015)
Number of employees
380 (2016)
Websitewww.ariad.com

ARIAD’s most prominent drug discoveries include Iclusig, designed for patients with all forms of Philadelphia chromosome-positive [Ph+] chronic myeloid leukemia (CML) or Ph+ acute lymphoblastic leukemia (ALL) who are resistant to or unable to tolerate other tyrosine kinase inhibitors, and brigatinib, a lung cancer drug which has completed its registration trial in ALK fusion driven non-small cell lung cancer as of June 2016 and was approved in the U.S. in April 2017.

In January 2017, Takeda announced it would acquire ARIAD for $5.2 billion, expanding the company's oncology and hematology business. On February 16, 2017, Takeda Pharmaceuticals, Ltd. announced it had completed its acquisition of ARIAD and incorporated ARIAD into Takeda Oncology.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.